^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Breast Cancer
    Drug:dovitinib (TKI258) (FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

    Excerpt:
    ...Tumor must have been tested by FISH/CISH for FGFR1 amplification....
    Trial ID:
    NCT00958971
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

    Excerpt:
    ...- Tumor must be available for central testing for FGFR1 amplification by FISH/CISH...
    Trial ID:
    NCT01484041
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

    Excerpt:
    In the FGFR1-amplified breast cancer group (n = 7), dovitinib induced a mean 20.2% reduction in tumor size (range, 28.4% increase to 100% reduction).
    DOI:
    10.1158/1078-0432.CCR-13-0190
    Trial ID:
    NCT00958971